Autoimmune Diseases Linked with Foot Drop
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is the primary autoimmune disease associated with foot drop, and foot drop improves to anti-gravity power in most treated CIDP patients. 1
Primary Autoimmune Cause: CIDP
CIDP presents with progressive proximal and distal symmetric weakness, sensory loss, and depressed reflexes that develops over at least 8 weeks, distinguishing it from acute presentations. 2 The disease is driven by innate and adaptive immune pathways that target peripheral nerve components, though the exact etiopathogenesis remains incompletely understood. 2
Foot drop is common in CIDP, and recovery data shows that after initiation of standard immunomodulating treatment, ankle dorsiflexion power improved to anti-gravity strength (≥3/5) in 63% of patients (17/27) within one year. 1
Predictors of Recovery in CIDP-Related Foot Drop
The strongest predictors of foot drop recovery are: 1
- Tibialis anterior compound muscle action potential amplitude at presentation (higher amplitude predicts better recovery)
- Shorter disease duration before treatment initiation
- Female gender
Pathophysiology
CIDP can damage peripheral nerves through two distinct mechanisms: 3
- Macrophage-induced demyelination at internodal areas
- Paranodal dissection (nodoparanodopathy) in cases with IgG4 antibodies against paranodal axoglial proteins, occurring without macrophage involvement
Approximately 30% of CIDP patients have immunoglobulin G that immunolabels nodes of Ranvier or paranodes of myelinated axons. 3
Secondary Autoimmune Cause: Guillain-Barré Syndrome (GBS)
While GBS is an acute autoimmune neuropathy (progressing over days to 4 weeks maximum), it can cause persistent foot drop requiring long-term management. 4, 5
GBS is triggered by preceding infections (Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae) and involves molecular mimicry where immune responses cross-react with peripheral nerves. 4
GBS Subtypes and Foot Drop Risk
- Acute inflammatory demyelinating polyneuropathy (AIDP): Most common in Europe and North America, causes rapidly progressive symmetric weakness including foot drop 4
- Acute motor axonal neuropathy (AMAN): More common in East Asia, targets gangliosides (GM1, GM1b, GD1a, GalNAc-GD1a) on motor axolemma causing axonal degeneration 4
Prognosis
GBS has approximately 10% mortality and 20% of patients are left with severe disability, which can include persistent foot drop requiring surgical intervention in refractory cases. 4, 5
Treatment Approach
For CIDP
Immunosuppressive and immunomodulating treatments are the cornerstone: 2
- Intravenous immunoglobulin (IVIg) therapy
- Plasma exchange
- Corticosteroids (though less effective as monotherapy)
Treatment should be initiated promptly, as shorter disease duration before treatment predicts better recovery of foot drop. 1
For GBS
High-dose IVIg and plasma exchange aid rapid resolution through: 4
- Complement inactivation
- Neutralization of idiotypic antibodies
- Cytokine inhibition
- Saturation of Fc receptors on macrophages
Critical pitfall: Corticosteroids alone do not alter GBS outcome and should not be used as monotherapy. 4
Diagnostic Considerations
When evaluating foot drop for autoimmune etiology: 2, 3
- Timeline is critical: Onset over <4 weeks suggests GBS; ≥8 weeks suggests CIDP
- Electrodiagnostic testing: Assess tibialis anterior compound muscle action potential amplitude (prognostic for recovery) 1
- Look for demyelinating features: Prolonged distal latencies, conduction velocity slowing, conduction block
- Test for antibodies: IgG4 antibodies against paranodal proteins in suspected nodoparanodopathy 3
Autonomic symptoms (orthostatic dizziness, syncope) may accompany these neuropathies and should be assessed. 6, 7